Prostate Cancer Excellence Forum

Prostate Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Interview

Dr Ellis Highlights Novel Approach That May Boost Prostate Cancer Immunotherapies

04/28/2021

Leigh Ellis, PhD, discusses efforts of Cedars-Sinai researchers to discover new ways to alter tissues surrounding prostate tumors to help the body fight cancer.

Leigh Ellis, PhD, discusses...

04/28/2021

Oncology

Videos

Dr Tagawa Reviews the Role of ADT in COVID-19 in Prostate Cancer

03/09/2021

Scott Tagawa, MD, MS FACP, discusses the impact of ADT on the clinical course of COVID-19 in patients with prostate cancer.

Scott Tagawa, MD, MS FACP,...

03/09/2021

Oncology

Podcasts

Dr Saad Highlights Results Following the ACIS Study

02/20/2021

Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.

Fred Saad, MD, discusses the...

02/20/2021

Oncology

Videos

Dr Feng Discusses Molecular Determinants of Response to APA in nmCRPC

02/20/2021

Felix Feng, MD, talks about identifying molecular determinants of response to apalutamide in nonmetastatic CRPC in the SPARTAN trial.

Felix Feng, MD, talks about...

02/20/2021

Oncology

Interview

Dr Cohen Reveals CCR Score May Offer ADT-Free Therapy in Higher-Risk Prostate Cancer

02/16/2021

Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.

Todd Cohen, MD, highlights how...

02/16/2021

Oncology

Videos

Dr Tward Discusses CCR Scores Accurately Guiding Treatment for Prostate Cancer

02/16/2021

Jonathan Tward, MD, discusses how the link between clinical cell-cycle risk score and post-RT metastasis can identify patients eligible to forgo combined ADT.

Jonathan Tward, MD, discusses...

02/16/2021

Oncology

Videos

Dr Chi Discusses Final Results Following the TITAN Study

02/16/2021

Kim Chi, MD, discusses final analysis results from the phase 3 TITAN trial of apalutamide vs placebo for patients with metastatic CSPC receiving ADT.

Kim Chi, MD, discusses final...

02/16/2021

Oncology

Videos

Alexandra Sokolova, MD, Talks Germline Testing for Veterans With Metastatic Prostate Cancer

12/28/2020

Dr Sokolova highlights a systematic approach to germline testing in veterans with metastatic prostate cancer.

Dr Sokolova highlights a...

12/28/2020

Oncology

Videos

Alexandra Sokolova, MD, Provides a Commentary on the GENTleMEN Study

10/28/2020

Dr Sokolova discusses the GENTleMEN study and important differences between somatic and germline testing for patients with prostate cancer.

Dr Sokolova discusses the...

10/28/2020

Oncology

Interview

Is the HULLK Key to Controlling Prostate Cancer Growth?

10/10/2019

Daniel Gioeli, PhD, and colleagues have found a potential key to regulating the progression of prostate cancer.

Daniel Gioeli, PhD, and...

10/10/2019

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology